Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on September 10, 2026 has been entered.
Response to Arguments
The rejection over Iwata is hereby withdrawn solely on the basis that the reference does indeed seem to indicate that the organohydrogensiloxane treats the alumina filler prior to the addition of other materials required by the claims, including the hydrosilylation catalyst and inhibitor. (Paragraph [0070] is confusing insofar as, at the same time that it teaches heating an admixture comprising the organohydrogensiloxane crosslinker and alumina particles to a temperature at which a dehydrogenation reaction involving hydrosilyl groups contributed by the organohydrogensiloxane and hydroxyl groups inherent in a metal oxide, it also seems to say that this reaction can aggravate storage stability. Nevertheless, the Examiner does agree that the totality of this passage is suggestive that they should be blended under conditions that facilitate this reaction and, thus, the organohydrogensiloxane “loses its identity” before the composition is fully assembled.
The Examiner did not find the remainder of Applicants’ arguments to be especially compelling and reiterates here that Iwata is considered to have been invalidated on this foundation alone.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 18-23 and 54 are rejected under 35 U.S.C. 103 as being unpatentable over Kato et al., EP 3533837 in view of Hu et al., WO 2020/093258 and/or U.S. 2018/0030327 and/or the YouTube video entitled “Application of Thermal Interface Material” available at the URL https://www.youtube.com/watch?v=AtTaAUd6-js.
Kato is directed to a thermally-conductive organopolysiloxane composition comprising at least the materials outlined in [0011], but also optionally a filler treating material (F) [0040+], silica as a thixotropic additive (G) [0054-0055], and other adjuvants defined in terms of the properties they convey/role they fulfill [0056].
Applicant is directed to Table 1 and the accompanying description of the materials used in paragraphs [0072-0080], but embodiment 5 in particular because it contains an amount of organohydrogensiloxane B-1 consistent with that claimed. (The vinyl-terminated polydiorganosiloxane, on the other hand, is added in quantities of about 4.8 wt.%, in all cases, which is slightly lower than the amount of the corresponding claimed first reactant in claims 18 and 54. At the same time, “ a prima facie case of obviousness exists where the claimed ranges and prior art ranges do not overlap but are close enough that one skilled in the art would have expected [the claimed product and a product disclosed in the prior art] to have the same properties.” Titanium Metals Corp. of America v. Banner, 778 F.2d 775, 227 USPQ 773 (Fed. Cir. 1985). Moreover, paragraph [0011] states that the amount of the vinyl-functional polyorganosiloxane may constitute 100 parts relative to 400-5000 parts of the filler, which of course is encompassing of various compositions for which the weight contribution of the former would be consistent with that claimed.) As an aside, A-1 in [0072] has a stated viscosity of 400 mPa.s and a linear polysiloxane of this viscosity would inherently have a number of repeat units between 2 and 2,000 as is required of claimed component (i).
The composition is assembled as outlined in [0081] where the filler is initially blended with the vinylsiloxane and other materials aside from the organohydrogensiloxane crosslinker and inhibitor followed by the addition of these. Whereas the amount of ethynyl cyclohexanol, at about 0.6 wt.%, is higher than that mandated, [0039] says that it may be incorporated in quantities as low as 0.001 parts relative to 100 parts of the vinylsiloxane.
As for the storage limitation, the Examiner is, once more, of the position that the prior art composition is formulated for commercial sale and, thus, while there is no express indication of it being stored prior to being used, its storage for at least a 24 hour period is plainly obvious. Further, while the Examiner now appreciates that ethynyl cyclohexanol, the inhibitor employed in embodiment 5 of Table 1, is known by one of ordinary skill not to stabilize a hydrosilylation-curable composition for the extended periods mandated by the claims, it is important to note that the platinum catalyst is encapsulated within an acrylic copolymer with a softening temperature of 115° C, thus affording stability below this temperature, and certainly above 40° C. Moreover, [0039] contemplates the employment of inhibitors such as 3,5-dimethyl-1-hexyn-3-ol, which are known to prevent premature curing of hydrosilylation-curable polysiloxanes for months- see page 6, lines 25+ and Table 1 of EP 451946 - and the substitution of this inhibitor for ethynyl cyclohexanol would be prima facie obvious. “It is prima facie obvious to substitute equivalents, motivated by the reasonable expectation that the respective species will behave in a comparable manner or give comparable results in comparable circumstances.” In re Ruff 118 USPQ 343; In re Jezel 158 USPQ 99; “the express suggestion to substitute one equivalent for another need not be present to render the substitution obvious.” In re Font, 213 USPQ 532.
While storage in a vessel, in general, would be obvious, a vessel featuring an orifice through which the composition would be dispensed at the time of application is not (obvious) based on the description of Kato by itself. However, Hu [0074], Zhang et al., and the YouTube video all demonstrate that administering a TIM composition from a syringe is a known, actually conventional, approach for applying the composition between a heat generating body and a heat radiating body ([0002] of Iwata), and, therefore, the packaging of the prior art composition in a vessel with an orifice, a syringe, would have been obvious at the time of the invention.
As for claim 23, none of the aforementioned references report a suitable diameter for the exit port/orifice of the syringe, although the syringe shown in the video looks to comply with the limitation of claim 17. The Examiner takes notice of the fact, however, that one of ordinary skill would select a syringe with orifice/opening sizes tailored to produce a “dot” or “line” of a particular diameter/width dictated by the particular application. To the extent that all of the references are directed to the same application as is the claimed composition, a syringe with a similar orifice diameter would be chosen.
Claims 31-53 are rejected under 35 U.S.C. 103 as being unpatentable over Kato et al., EP 3533837 in view of Hu et al., WO 2020/093258 and/or U.S. 2018/0030327 and/or the YouTube video entitled “Application of Thermal Interface Material” available at the URL https://www.youtube.com/watch?v=AtTaAUd6-js as applied to claims 18-23 and 54 above, and further in view of Iwata et al., WO 2021/095501.
Independent claims 31, 38, 43, and 47 all differ from independent claims 18 and 54 in that they stipulate an initial viscosity reported in terms of a viscosity range at 1 s-1 and 100 s-1 measured at 25° C. Kato actually does disclose a viscosity range taken at 1 s-1 – see [0065]- of 180 Pa.s for embodiment 5. It is conceded, though, that the reference does not address a viscosity at 100 s-1, which makes sense insofar as it is silent as to the use of a syringe for dispensing the thermal interface materials set forth therein. Iwata advises in [0107] that the viscosity should be optimized so that a suitable balance of shape retention and workability is realized. “Discovering an optimum value of a result effective variable involves only routine skill in the art.” In re Boesch, 617 F.2d 272, 205 USPQ 215 (CCPA 1980).
The Examiner realizes that this passage alludes to a viscosity at 6 s-1 but the entire prosecution record makes clear that it was the more general teachings of paragraph [0107] that were being relied upon to establish viscosity at 1 s-1 (approximate shear rate of gravity) and 100 s-1 (approximate wall shear rate experienced by the composition when it’s expelled through a syringe) as being result effective variables that one a skilled practitioner of the invention defined by the combined teachings of Kato and Hu would optimize. Indeed, the Examiner states repeatedly that there was not an attempt to estimate a viscosity at 1 s-1 and 100 s-1 from a figure reported at 6 s-1. These more general teachings are supported by the 11/15/19 priority document at paragraph [0059]. Also, this teaching is regarded as applicable to both a one-part composition, and a two-part composition after the parts have been combined.
Claims 31 and 47 mandate that the inhibitor be selected from a maleate or fumarate, as opposed to the ETCH used in embodiment 5 of Kato. Once more, Iwata establishes alkyl maleates as being functional equivalents of the ethynyl cyclohexanol.
Regarding claim 35, it is noted that fumed silica with a high specific surface area, a known thixotrope, is added to embodiment 5 and Table 1 references a thixotropy ratio in association with the exemplary compositions.
Concerning claims 36, 40, and 43, the prior art does not appear to anywhere characterize the durometer of the filled elastomer derived from the prior art composition but, rather, only discloses its Shore 00 hardness in a pre-cured state, both initially and after storage. Again, because the claimed- and prior art compositions have similar utility, it is the Examiner’s position that one of ordinary skill would aim to formulate a composition with a comparable post-cure hardness.
As for claim 41, a syringe filled with a composition of very similar makeup, and with a comparable initial viscosity, ejected from a syringe with an applied pressure of 90 psi will necessarily exhibit a flow rate of the composition consistent with that recited.
As for claims 42 and 53, none of the aforementioned references report a suitable diameter for the exit port/orifice of the syringe, although the syringe shown in the video looks to comply with the limitation of claim 17. The Examiner takes notice of the fact, however, that one of ordinary skill would select a syringe with orifice/opening sizes tailored to produce a “dot” or “line” of a particular diameter/width dictated by the particular application. To the extent that all of the references are directed to the same application as is the claimed composition, a syringe with a similar orifice diameter would be chosen.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARC S ZIMMER whose telephone number is (571)272-1096. The examiner can normally be reached M-F 8:30-5:00.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heidi Kelley can be reached at 571-270-1831. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
October 28, 2026
/MARC S ZIMMER/Primary Patent Examiner, Art Unit 1765